FT : Hedge fund Caxton suffers in choppy year for bond markets

Hedge fund Caxton suffers in choppy year for bond markets
Firm headed by Andrew Law finishes 2023 down 9% in its Macro fund

Caxton Associates, one of the oldest and best-known global macro hedge fund managers, lost money in its two main funds in 2023, say two people who have seen the numbers, in a turbulent year for bond markets.

The London-based firm, headed by Andrew Law, lost 9.2 per cent in its Caxton Macro fund, while its flagship Caxton Global Investments fund lost about 1 per cent. The macro fund takes more concentrated bets than the flagship.

Caxton did not immediately respond to a request for comment.

The macro fund was down as much as about 20 per cent last year, following losses in the first half of the year, but made back some ground in the remainder of 2023, investors said.

“At the start of the year there was so much volatility in rates the fund got whipped around,” said a person close to the firm.

Caxton was founded in 1983 by Bruce Kovner. Global macro funds trade moves in bonds, currencies, commodities and equities on the back of economic trends.

The performance figures punctuate a challenging year for macro hedge funds. After a sharp sell-off in debt markets at the start of the year, as central banks raised interest rates to fight inflation, bond prices rocketed as the collapse of Silicon Valley Bank sparked a flight to safety, taking many hedge funds by surprise.

Caxton’s losses last year mark a change in fortunes after strong gains in 2022, when the macro fund was up roughly 35 per cent. 

Brevan Howard, another prominent global macro manager, also had a tough year in 2023. Its flagship fund was down 2.1 per cent while its Alpha Strategies fund was up 2.4 per cent, according to people who have seen the figures. 

However, Rokos Capital Management, run by former Brevan Howard co-founder Chris Rokos, ended 2023 up 8.8 per cent. BlueCrest Capital, the family office of billionaire trader Mike Platt, gained 20.3 per cent last year, according to people familiar with the performance.

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • BGFV -6.5%, FULT -3.8%, IBKR -3.6%, PLXS -2% (lowers DecQ guidance, citing inventory corrections and weaker demand in Healthcare/Lifesciences and Industrial markets; also announces new $50 mln share repurchase program), CFG -1.9%, PNFP -1.7%, MANU -0.9%, USB -0.6%
Other news:
  • DH -13.3% (CEO steps down reaffirms Q4 guidance)
  • ALEC -7.7% (stock offering)
  • GOL -7.4% (comments on media reports - is in discussions with its financial stakeholders to achieve the aforementioned consensual restructuring)
  • INTR -6% (stock offering by selling shareholders)
  • CVGW -5.6% (delays Q4 report expects revs below consensus; delays 10-K filing board says certain matters merit "enhanced evaluation"; also exploring sale of its Fresh Cut Business to F&S Fresh Foods)
  • SPWR -2% (adopts restructuring plan to reduce operating costs due to slower sales)
  • HLN -1.3% (GlaxoSmithKline completes sale of shares in Haleon)
  • MS -1.1% (Direct Lending Fund commences 5 mln share IPO)
  • BP -1% (appoints Murray Auchincloss as CEO; to acquire GETEC ENERGIE GmbH)
Analyst comments:
  • ALLK -10.1% (downgraded to Hold from Buy at Jefferies)
  • AXL -3.3% (downgraded to Sell from Neutral at UBS)
  • DXC -3.1% (downgraded to Sell from Neutral at Citigroup)
  • F -1.7% (downgraded to Neutral from Buy at UBS)
  • FTNT -1.1% (downgraded to Equal Weight from Overweight at CapitalOne)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • PI +12.5%, NNBR +4.7% (guidance), EOLS +4.5%, PRGS +4%
Other news:
  • NTRA +8.1% (verdict reached in patent case; no willful infringement damages significantly less than what Ravgen was seeking)
  • RCUS +4.9% (RCUS announces survival data from ARC-8 a Phase 1b study co-developed with GILD)
  • TFPM +3.5% (reports Q4 revenue above consensus metal sales of 26243 gold equivalent ounces)
  • IXHL +3.4% (received approval to commence a Phase 2/3 clinical trial)
  • SBGI +2.1% (announces global settlement of all diamond sports group-related litigation issues including agreement with diamond on management services agreement amendment)
  • NRIX +1.9% (receives FDA Fast Track Designation for NX-5948)
  • ENLC +1.8% (expands 2023 common unit repurchase auth of $250 mln authorizes 2024 $200 mln repurchase plan increases distribution)
  • EU +1.8% (provides update on South Texas uranium operations)
  • ALB +1.6% (outlined a series of proactive measures underway to re-phase its organic growth investments and optimize its cost structure)
  • REPX +0.9% (reduces debt outstanding by $30 mln)
  • CBUS +0.8% (announces that the Company is moving forward in the next step of commercialization of its developed traits) .
Analyst comments:
  • CART +3% (upgraded to Outperform from Peer Perform at Wolfe Research)
  • EXLS +1.5% (upgraded to Buy from Neutral at Citigroup)

>>> US Research Calls

Research Calls
  • Upgrades:
    • Automatic Data (ADP) upgraded to Neutral from Underperform at BofA Securities; tgt raised to $243
    • Burlington Stores (BURL) upgraded to Overweight from Neutral at Piper Sandler; tgt raised to $240
    • CNH Industrial (CNHI) upgraded to Buy from Neutral at Goldman; tgt $19
    • ExlService (EXLS) upgraded to Buy from Neutral at Citigroup; tgt raised to $36
    • Futu Holdings (FUTU) upgraded to Overweight from Neutral at JP Morgan; tgt $64
    • Instacart (CART) upgraded to Outperform from Peer Perform at Wolfe Research; tgt $35
  • Downgrades:
    • Allakos (ALLK) downgraded to Hold from Buy at Jefferies; tgt lowered to $1.50
    • American Axle (AXL) downgraded to Sell from Neutral at UBS; tgt lowered to $6.50
    • CrowdStrike (CRWD) downgraded to Hold from Buy at WestPark Capital
    • DXC Technology (DXC) downgraded to Sell from Neutral at Citigroup; tgt lowered to $21
    • Fisker (FSR) downgraded to Market Perform from Outperform at TD Cowen; tgt lowered to $1
    • Ford Motor (F) downgraded to Neutral from Buy at UBS; tgt $12
    • Fortinet (FTNT) downgraded to Equal Weight from Overweight at CapitalOne
  • Others:
    • Accolade (ACCD) resumed with a Neutral at DA Davidson; tgt lowered to $14
    • American Coastal Insurance Corporation (ACIC) initiated with an Outperform at Raymond James; tgt $15
    • Aramark (ARMK) initiated with a Buy at Goldman; tgt $33
    • AutoNation (AN) initiated with an Outperform at Evercore ISI; tgt $185
    • E2open (ETWO) initiated with an Equal-Weight at Morgan Stanley; tgt $4
    • Global-E Online (GLBE) initiated with an Overweight at Wells Fargo; tgt $50

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • NTRA +9.5%, PI +7.7%, RCUS +4.9%, PRGS +2.9%, EOLS +2.4%, SBGI +2.1%, NRIX +1.9%, ENLC +1.8%, CMP +0.9%, WAFD +0.8%
  • Gapping down:
    • GOL -10.9%, BGFV -10.2%, ALEC -9.8%, CVGW -5.6%, IBKR -4.6%, FULT -4.4%, PLXS -4%, INTR -3.2%, DH -3%, SPWR -3%, PNFP -1.7%, HLN -1.6%, BP -1.4%, CRSP -1.3%, MS -1.2%, ACHR -1.2%, PAAS -1.2%, GPRO -0.9%

>>> Manchester United misses single estimate on top and bottom lines; lowers gui

Manchester United misses single estimate on top and bottom lines; lowers guidance (21.20)
  • Reports Q1 EPS of (GBP0.05) vs GBP0.03 single estimate; revs of GBP157.1 mln vs GBP175.0 mln single estimate
  • Outlook
    • For fiscal 2024, the Company is forecasting revenue guidance to be within a range of £635 million to £665 million from prior guidance of £650 million to £680 million and adjusted EBITDA guidance to be within a range of £125 million to £150 million from prior guidance of £140 million to £165 million, owing to the early Champions League exit and related reduction in Broadcasting revenues.